Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at FBR & Co
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating restated by FBR & Co in a report released on Monday.
Other equities research analysts also recently issued research reports about the company. Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the company a “buy” rating in a report on Monday, January 9th. Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.27 price objective for the company. in a report on Thursday, January 5th. Credit Suisse Group AG set a $50.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 25th. Needham & Company LLC reissued a “buy” rating and issued a $98.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, December 20th. Finally, Jefferies Group LLC set a $58.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, December 1st. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus price target of $64.53.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 8.07% during midday trading on Monday, reaching $59.71. 1,668,073 shares of the company’s stock were exchanged. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $80.11. The company’s market cap is $5.14 billion. The company has a 50 day moving average price of $47.17 and a 200 day moving average price of $48.26.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.02. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. The firm earned $17.50 million during the quarter, compared to the consensus estimate of $10.66 million. During the same quarter in the prior year, the firm posted ($1.07) EPS. The business’s revenue was up 130.3% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post ($5.08) EPS for the current year.
Your IP Address:
In related news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $37.95, for a total value of $569,250.00. Following the sale, the director now owns 155,795 shares in the company, valued at approximately $5,912,420.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mn Services Vermogensbeheer B.V. boosted its position in Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 87 shares during the last quarter. Hall Laurie J Trustee purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $160,000. Neuberger Berman Group LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $205,000. Notis McConarty Edward purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $229,000. Finally, Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $266,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.